Detection of Aneuploidy in Cerebrospinal Fluid from Patients with Breast Cancer Can Improve Diagnosis of Leptomeningeal Metastases

Purpose: Detection of leptomeningeal metastasis is hampered by limited sensitivities of currently used techniques: MRI and cytology of cerebrospinal fluid (CSF). Detection of cell-free tumor DNA in CSF has been proposed as a tumor-specific candidate to detect leptomeningeal metastasis at an earlier stage. The aim of this study was to investigate mutation and aneuploidy status in CSF-derived cell-free DNA (cfDNA) of patients with breast cancer with a clinical suspicion of leptomeningeal metastasis. Experimental Design: cfDNA was isolated from stored remnant CSF and analyzed by targeted next-generation sequencing (NGS; n = 30) and the modified fast aneuploidy screening test-sequencing system (mFAST-SeqS; n = 121). The latter method employs selective amplification of long interspaced nuclear elements sequences that are present throughout the genome and allow for fast and cheap detection of aneuploidy. We compared these results with the gold standard to diagnose leptomeningeal metastasis: cytology. Results: Leptomeningeal metastasis was cytology proven in 13 of 121 patients. Low DNA yields resulted in insufficient molecular coverage of NGS for the majority of samples (success rate, 8/30). The mFAST-SeqS method, successful in 112 of 121 (93%) samples, detected genome-wide aneuploidy in 24 patients. Ten of these patients had cytology-proven leptomeningeal metastasis; 8 additional patients were either concurrently diagnosed with central nervous system metastases by radiological means or developed these soon after the lumbar puncture. The remaining six cases were suspected of leptomeningeal metastasis, but could not be confirmed by cytology or imaging. Aneuploidy was associated with development of leptomeningeal metastasis and significantly worse overall survival. Conclusions: Aneuploidy in CSF-derived cfDNA may provide a promising biomarker to improve timely detection of leptomeningeal metastasis.

[1]  J. Schellens,et al.  Circulating epithelial tumor cell analysis in CSF in patients with leptomeningeal metastases , 2020, Neurology.

[2]  S. Sleijfer,et al.  The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies , 2019, Nature Genetics.

[3]  R. Datar,et al.  Untargeted Assessment of Tumor Fractions in Plasma for Monitoring and Prognostication from Metastatic Breast Cancer Patients Undergoing Systemic Treatment , 2019, Cancers.

[4]  R. Cimaz,et al.  Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis , 2019, Front. Pharmacol..

[5]  S. Sleijfer,et al.  Novel methods to diagnose leptomeningeal metastases in breast cancer , 2018, Neuro-oncology.

[6]  S. Chuai,et al.  Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  L. Deangelis,et al.  Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors , 2017, Neuro-oncology.

[8]  M. J. van den Bent,et al.  EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  J. Westerga,et al.  EpCAM-based flow cytometry in cerebrospinal fluid greatly improves diagnostic accuracy of leptomeningeal metastases from epithelial tumors. , 2016, Neuro-oncology.

[10]  John A. Foekens,et al.  Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen , 2016, Oncotarget.

[11]  A. Viale,et al.  Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Salvatore Piscuoglio,et al.  Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma , 2015, Nature Communications.

[13]  H. Rugo,et al.  Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer , 2015, Breast Cancer Research and Treatment.

[14]  Peter Ulz,et al.  Rapid Identification of Plasma DNA Samples with Increased ctDNA Levels by a Modified FAST-SeqS Approach. , 2015, Clinical chemistry.

[15]  M. Martínez-García,et al.  Diagnostic and prognostic significance of flow cytometry immunophenotyping in patients with leptomeningeal carcinomatosis , 2015, Clinical & Experimental Metastasis.

[16]  L. Diaz,et al.  Liquid biopsies: genotyping circulating tumor DNA. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  L. Deangelis,et al.  Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumors , 2013, Neurology.

[18]  S. Taillibert,et al.  A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer , 2013, Journal of Neuro-Oncology.

[19]  M. Murawska,et al.  Breast cancer leptomeningeal metastasis: propensity of breast cancer subtypes for leptomeninges and the analysis of factors influencing survival , 2013, Medical Oncology.

[20]  K. Kinzler,et al.  FAST-SeqS: A Simple and Efficient Method for the Detection of Aneuploidy by Massively Parallel Sequencing , 2012, PloS one.

[21]  M. Melamed,et al.  Malignant cells in cerebrospinal fluid (CSF): The meaning of a positive CSF cytology , 2011, Neurology.

[22]  S. Peres,et al.  Meningeal carcinomatosis in breast cancer: prognostic factors and outcome , 2011, Journal of Neuro-Oncology.

[23]  M. Chamberlain.  Leptomeningeal metastases in the MRI era , 2011, Neurology.

[24]  F. Bidard,et al.  Survival of breast cancer patients with meningeal carcinomatosis. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  C. Straathof,et al.  The diagnostic accuracy of magnetic resonance imaging and cerebrospinal fluid cytology in leptomeningeal metastasis , 1999, Journal of Neurology.

[26]  J. Hammack,et al.  Leptomeningeal Carcinomatosis: Presenting Features and Prognostic Factors , 1996 .

[27]  J. Lamovec,et al.  Metastatic pattern of infiltrating lobular carcinoma of the breast: An autopsy study , 1991, Journal of surgical oncology.

[28]  J. Posner,et al.  Diagnosis and treatment of leptomeningeal metastases from solid tumors: Experience with 90 patients , 1982, Cancer.

[29]  A. J. Dale,et al.  Meningeal carcinomatosis. Clinical manifestations. , 1974, Archives of neurology.

[30]  J. Posner,et al.  Infiltration of the leptomeninges by systemic cancer. A clinical and pathologic study. , 1974, Archives of neurology.

[31]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[32]  M. Martínez-García,et al.  Role of flow cytometry immunophenotyping in the diagnosis of leptomeningeal carcinomatosis. , 2012, Neuro-oncology.

[33]  M. Høyer,et al.  [Meningeal carcinomatosis]. , 2005, Ugeskrift for laeger.